Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells

<div>Typical dose curves of PSL, 114, and PSL + 114 for the proliferation of ConA-activated PBMCs from healthy subjects (n = 6). ConA: concanavalin A, PBMCs: peripheral blood mononuclear cells, PSL: prednisolone, and 114: saireito.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells 

Figure 2 | Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells 